Product Overview
[Drug Name]
Generic Name: Pasniazid Tablets
Trade Name: Likefeizuo Pasniazid Tablets 100mg*100 Tablets
Pinyin Code: LiKeFeiZuo PaSiYanZuoPian100mg*100Tablets
[Main Ingredients]
The main ingredient of this product is para-aminosalicylic acid isoniazid.
[Properties]
This product is a film-coated tablet.
[Indications/Main Functions]
In combination with other anti-tuberculosis drugs, it is used to treat various types of pulmonary, endobronchial, and extrapulmonary tuberculosis. It can also be used as a protective drug for tuberculosis-related surgery and to prevent tuberculosis infection and recurrence following long-term or high-dose corticosteroid or immunosuppressive therapy.
[Specifications]
100mg*100 tablets (Likefeizuo)
[Dosage and Administration]
Oral. For treatment in combination with other anti-TB drugs: Adults: 10-20 mg/kg daily (6-12 tablets per day); Children: Increase to 20-40 mg/kg daily (3-6 tablets per day) as needed, orally in three divided doses or all at once. For prevention: 10-15 mg/kg daily (3-6 tablets per day) orally in three divided doses or all at once.
[Adverse Reactions]
Occasional adverse reactions may include dizziness, headache, insomnia, fever, rash, nausea, fatigue, jaundice, peripheral neuritis, optic neuritis, and hematocrit.
[Contraindications]
1. Contraindicated in patients with mental illness and epilepsy.
2. Contraindicated in patients with severe liver dysfunction.
[Drug Interactions]
Drug interactions may occur if used concurrently with other medications. Consult your physician or pharmacist for details.
[Precautions]
1. This product should be taken continuously for at least three months. If no adverse reactions occur, it should not be discontinued midway. Discontinuation of treatment is recommended only after clinically confirmed recovery.
2. Use with caution in pregnant women, those with impaired liver and kidney function, and those with a history of mental illness, epilepsy, or brain trauma.
3. Liver function tests should be performed regularly during treatment. A few patients may experience transient elevations in aminotransferase levels during the first two months of treatment. Continued treatment with liver-protective therapy can restore aminotransferase levels to normal. If elevations persist, the drug should be discontinued.
4. If symptoms of optic neuritis develop during treatment, an eye examination should be performed immediately and followed up regularly.
5. Concomitant administration of vitamin B6 can prevent and treat adverse neurological reactions such as peripheral neuritis.
6. Antacids, especially aluminum hydroxide, can inhibit the absorption of this drug and should not be taken concomitantly.
7. This drug may enhance the effects of coumarin anticoagulants, certain antiepileptic drugs, antihypertensive drugs, anticholinergics, and tricyclic antidepressants; caution is advised when using this drug together.
[Pediatric Use]
Unknown.
[Elderly Use]
Unknown.
[Overdose]
Unknown.
[Pharmacology and Toxicology]
1. Pharmacology: This product is a chemical synthesis of isoniazid (INH) and para-aminosalicylic acid (PAS). INH is primarily effective against mycobacteria during their growth and proliferation phase. Its mechanism of action is not yet elucidated, but it may inhibit the synthesis of mycolic acids in sensitive bacteria, leading to cell wall rupture. PAS effectively delays and blocks the acetylation process of INH in the body. As a result, this product maintains higher and longer-lasting INH concentrations in the blood and reduces liver toxicity. Clinically, after taking equal doses of INH and this product, the blood concentration of INH was only 0.03 mg/L after 12 hours, while that of this product was 2.6 mg/L. After 14 hours, the blood concentration of INH had reached zero, while that of this product was still as high as 2 mg/L, twice the MIC. This not only enhances the bactericidal effect of the drug but also delays the development of bacterial resistance. Clinically, this product has been shown to be significantly more effective than INH in combination therapy with other anti-tuberculosis drugs, while the incidence of adverse reactions such as gastrointestinal reactions, liver damage, and leukopenia is significantly lower than that of INH. Animal studies have shown that in artificially infected mice, this product's anti-tuberculosis efficacy is approximately five times that of INH. A daily dose of 10 mg/kg of this product significantly outperforms a physical mixture of INH (20 mg/kg daily) and PAS (200 mg/kg daily).
2. Toxicology: The oral LD50 values for mice and rabbits are 0.4 g/kg/day and 0.8-1.6 g/kg, respectively, twice that of INH.
